HIV-1-infection
Conditions
Keywords
HIV -1, elsulfavirine fixed-dose combination
Brief summary
Open-label, randomized, parallel-group, comparative study of pharmacokinetics and bioequivalence of VM-1500FDC (elsulfavirine/emtricitabine/tenofovir fixed-dose combination) and Elpida® with Truvada® (emtricitabine/tenofovir) co-administered by healthy male subjects. The study will also assess safety profile of study drugs.
Detailed description
The study assesses PK and bioequivalence of the developed new drug VM-1500FDC - a fixed combination of three active substances: elsulfavirine (NNRTI), emtricitabine (NRTI) and tenofovir (NRTI) to Elpida® and Truvada® co-administered. The combination is intended for once daily administration (1 tablet) for the treatment of HIV-1 infection in adult patients. Thus, the purpose of this combination is to simplify the dosage regimen and improve patient compliance
Interventions
Sponsors
Viriom
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Non-smoking male subjects between the ages of 20 and 40 years (inclusive); 2. Verified diagnosis of healthy according to standard clinical, laboratory and instrumental examination methods; 3. Body weight from 60 to 95 kg and Body Mass Index from 19.0 to 27.0 kg/m; 4. A negative result in tests for alcohol and drugs; 5. The subject's consent to use adequate contraception methods during the study and 3 month after end of study: condom with spermicide (foam, gel, cream, suppositories); 6. Signed the Participant Explanation Sheet and the Informed Consent Form.
Exclusion criteria
1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood; 2. Variables of standard laboratory and instrumental parameters are beyond the normal limits Variables of standard laboratory and instrumental parameters are beyond the normal limits (taking into account the acceptable limits of laboratory parameters); 3. Surgical interventions on the gastrointestinal tract in medical history (except appendectomy); 4. Systolic pressure less than 90 mm Mercury or above 130 mm Mercury, diastolic pressure less than 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more than 90 BPM at screening; 5. Regular intake of drugs less than 2 weeks prior to screening (including herbal preparations and dietary supplements); intake of drugs that have a pronounced effect on hemodynamics, liver function, etc. (for example, barbiturates, omeprazole, cimetidine, etc.) less than 30 days prior to screening; 6. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface antigen, a positive syphilis test; 7. An unstable sleep structure (e.g., night work, sleep disorders, insomnia, recent return from another time zone, etc.), extreme physical activity (e.g. weight lifting), a special diet (e.g. vegetarian, vegan); 8. Signs of alcohol (taking more than 10 units of alcohol per week ) or drug addiction; alcohol or drugs consumption within 4 days prior to screening; cigarettes smoking 3 months prior to screening; positive drug and/or alcohol test; 9. Burdened allergic medical history (including drug intolerance and food allergy); 10. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption; 11. Hypersensitivity to tenofovir, elsulfavirine or emtricitabine, as well as any other component of the study drugs; 12. Blood/plasma donation (450 ml of blood or plasma and more) less than 2 months prior to screening; 13. Treatment with a study drug in framework of other clinical trials within 30 days prior to screening (including follow-up visits); 14. Acute infectious diseases less than 4 weeks prior to screening; 15. Incapable of reading or writing; no desire to understand and adhere to the study protocol procedures; non-compliance with the drugs intake regimen or execution of procedures, which as the Investigator may think may affect the study results or subject's safety and prevent the subject from further participation in the study; any other associated medical or serious psychological conditions making the subject not eligible to participate in the clinical study, restricting legality of obtaining the informed consent or affecting the subject's ability to take part in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of VM1500A | 29 days |
| Plasma concentration of elsulfavirine | 29 days |
| Plasma concentration of emtricitabine | 29 days |
| Plasma concentration of tenofovir | 29 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of AEs and SAEs | 29 days | Frequency and severity of AE, recorded after administration of the drug according to subjective complaints, changes in vital signs, ECG, laboratory results and physical examination compared to the baseline |
Countries
Russia
Outcome results
None listed